Jefferies Financial Group Inc. Purchases 2,254,219 Shares of Nkarta, Inc. (NASDAQ:NKTX)

Jefferies Financial Group Inc. raised its position in shares of Nkarta, Inc. (NASDAQ:NKTX) by 901.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,504,219 shares of the company’s stock after acquiring an additional 2,254,219 shares during the period. Jefferies Financial Group Inc. owned approximately 3.55% of Nkarta worth $6,236,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Invesco Ltd. bought a new stake in shares of Nkarta in the fourth quarter valued at approximately $30,000. Sequoia Financial Advisors LLC bought a new stake in shares of Nkarta in the fourth quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Nkarta in the fourth quarter valued at approximately $37,000. Catalina Capital Group LLC boosted its stake in shares of Nkarta by 57.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company’s stock valued at $47,000 after buying an additional 6,867 shares during the period. Finally, Sei Investments Co. bought a new stake in shares of Nkarta in the fourth quarter valued at approximately $57,000. Institutional investors own 80.54% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on NKTX shares. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price target on shares of Nkarta in a research note on Wednesday, April 9th. Stifel Nicolaus cut their price target on Nkarta from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Thursday, March 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Nkarta in a research note on Thursday, March 27th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Nkarta currently has an average rating of “Buy” and an average target price of $14.83.

Nkarta Price Performance

NASDAQ NKTX opened at $1.95 on Monday. The business has a fifty day moving average price of $1.78 and a two-hundred day moving average price of $2.24. Nkarta, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $8.23. The stock has a market capitalization of $138.01 million, a PE ratio of -1.03 and a beta of 0.81.

Nkarta (NASDAQ:NKTX) last released its earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.06. As a group, sell-side analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.